title: Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
authors.forename: Fernanda
authors.initials: F
authors.lastname: Genre
authors.forename: José A
authors.initials: JA
authors.lastname: Miranda-Filloy
authors.forename: Raquel
authors.initials: R
authors.lastname: López-Mejias
authors.forename: Beatriz
authors.initials: B
authors.lastname: Carnero-López
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Ochoa
authors.forename: Javier
authors.initials: J
authors.lastname: Rueda
authors.forename: Carlos
authors.initials: C
authors.lastname: González-Juanatey
authors.forename: Ricardo
authors.initials: R
authors.lastname: Blanco
authors.forename: Javier
authors.initials: J
authors.lastname: Llorca
authors.forename: Miguel A
authors.initials: MA
authors.lastname: González-Gay
mesh_terms: D042702:Angiopoietin-2 / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D006801:Humans; D000069285:Infliximab; D013167:Spondylitis, Ankylosing / Q000097:blood / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D042702:Angiopoietin-2; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: Ankylosing Spondylitis; Anti-TNF; Atherosclerosis; Inflammation